RxDoctor Payments Data

Jamie Kelly

Physician Assistant · Shrewsbury, NJNPI 1891421376

Payments from drug & device makers

$3,570in general payments, 2019–2025

Across 135 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Dendreon Pharmaceuticals LLC$342
  • Sumitomo Pharma America, Inc.$218
  • Myriad Genetic Laboratories, Inc.$210
  • 180 Medical, Inc.$177
  • Antares Pharma, Inc.$157
  • plus $1K from 24 others

What the payments were for

  • Travel & lodging$1,01228%
  • Food & beverage$2,55872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,570 in reported general payments places this provider in the 90th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$17,920
Medicare patients
104
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron37$28,712
GemtesaVibegron32$28,348
Tamsulosin Hcl195$4,190
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst129$1,765
Testosterone14$1,245
Finasteride64$973
Methenamine Hippurate12$758
Oxybutynin Chloride ErOxybutynin Chloride47$726
Potassium Citrate ErPotassium Citrate11$405
Solifenacin Succinate19$364
NitrofurantoinNitrofurantoin Macrocrystal13$321
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$274
Cephalexin29$252
Ciprofloxacin Hcl42$224
Doxycycline Hyclate15$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$49$28,71237 claims
Sumitomo Pharma America, Inc.Gemtesa$218$28,34832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Shrewsbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →